Open Access<p>DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro</p>
Author(s) -
Yao Huang,
Jianxing Zeng,
Teng Li,
Qingyi Xu,
Xianglin Song,
Jinhua Zeng
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s253565
Subject(s) - chimeric antigen receptor , cd28 , interleukin 21 , cytotoxic t cell , immunotherapy , cancer immunotherapy , cancer research , interleukin 12 , lymphokine activated killer cell , flow cytometry , cytokine induced killer cell , natural killer t cell , t cell , cancer cell , chemistry , biology , antigen , immunology , cancer , immune system , in vitro , cd3 , cd8 , genetics , biochemistry
Hepatocellular cancer (HCC) is the sixth most prevalent cancer and the third leading cause of cancer-related death worldwide. Cellular immunotherapy against glypican 3 (GPC3) has recently been used in the treatment of HCC, following the success of chimeric antigen receptor (CAR)-T therapy in treatment of B cell malignancy. However, CAR-T cells are not "off-the-shelf" and always cause cytokine release syndrome, which can be eliminated by using natural killer (NK) cells as effector cells. Since a costimulatory signal is necessary for the activation, persistence, or cytotoxicity of CAR-T cells, we speculated that the costimulatory signal is also required for CAR-NK cells in HCC treatment.